Clinical Trials featured content on bio
-
Don’t Take It For Granted
3/20/2013
Investigator grant payments are typically the single greatest expense in a clinical trial budget, often accounting for 40 to 60 per cent of the total budget. By Kevin Williams, CFS Clinical
-
Responding To Market Volatility In The Clinical Space
11/15/2012
At the 2012 AAPS meeting in Chicago, Clinical Leader sat down with Chad Briscoe, Ph.D., senior director of PRA’s Bioanalytical Laboratory in Lenexa, KS. Briscoe took time out to share his insights on strategic partnering and how PRA’s expansion of services is being driven by market demand.
-
Demystifying Fair Market Value
9/28/2012
Confusion exists over the definition of fair market value (FMV) when you ask any biopharmaceutical sponsor or investigative site and this article attempts to demystify some
basic factors related to FMV principles, with the goal of fostering improved understanding and dialogue on FMV issues. -
Developing A Strategic Relationship – Amgen And PRA
6/21/2012
When new opportunities arise and sponsor companies are vetting CROs or partners for their work, they look first to their existing relationships. Then, particularly for new development areas such as biosimilars, they look at the entire landscape for other organizations that have specific expertise in that field. By Rob Wright